Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | FGF1 | P05230 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248647 | 0.93 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL9604424 | 0.93 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL17589419 | 0.92 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL27416867 | 0.90 | LMNA (0.51) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL27416844 | 0.84 | LMNA (0.48) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL16248678 | 0.84 | LMNA (0.43) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL27416853 | 0.84 | LMNA (0.49) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL26481973 | 0.83 | LMNA (0.48) | ALDH1A1LMNAKMT2AMAPK1CYP2D6 | |
| SCHEMBL15829782 | 0.83 | TDP1 (0.42) | ALDH1A1LMNAKMT2AMAPK1LGALS8 | |
| SCHEMBL10226142 | 0.83 | TDP1 (0.42) | ALDH1A1LMNAKMT2AMAPK1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160354476-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9382540-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160090596-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090595-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160076030-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9181549-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354476-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | FUT6, GALNT6, FUT5 | ALDH1A1 1445/4885LMNA 993/4885KMT2A 1069/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | ALDH1A1 1286/4885LMNA 885/4885KMT2A 3611/4885 |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885LMNA 930/4885KMT2A 2674/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | ALDH1A1 3686/4885LMNA 823/4885KMT2A 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.